Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Gastroenterology

Journal Scan / Research · December 04, 2024

Association of Risankizumab Concentration and IL-22 Levels With Clinical and Biochemical Remission of Crohn's Disease

Clinical Gastroenterology and Hepatology

 

Additional Info

Disclosure statements are available on the authors' profiles:

Clinical Gastroenterology and Hepatology
Risankizumab Concentration but not IL-22 Levels Are Associated With Clinical and Biochemical Remission in Patients With Crohn's Disease
Clin. Gastroenterol. Hepatol. 2024 Nov 01;22(11)2340-2343.e2, X Roblin, E Moschetti, M Barrau, AS Cheifetz, K Papamichael, S Paul

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading